Endocrine Abstracts

Background and aims: The efficacy and safety of dapagliflozin as add-on therapy in patients with type 2 diabetes mellitus (T2DM) and inadequate glycemic control with evogliptin and metformin combinations was investigated.Materials and methods: Patients with HbA1c of 7.0% to 10.5% receiving evogliptin 5mg and metformin ≥1000 mg were randomized to receive dapagliflozin 10 mg/day (n=99) or placebo (n=99) for 24 weeks. The primary end...

Recently, dipeptidyl peptidase-IV (DPP-IV) inhibitor, a major anti-hyperglycaemic agent, has received substantial attention as a possible therapeutic target for inflammatory diseases such as atherosclerosis. However, the direct molecular mechanisms through which DPP-IV inhibitor mediates anti-inflammatory effects in vascular endothelial cells have not been clarified. The effects of the DPP-IV inhibitor, gemigliptin, were analysed in human umbilical vein endothelial cells (HUVE...